Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Read now
Aaminah Faheem Azhar, Rachael Camille Saporito & Jordan Jamerson. (2021) Erythema multiforme after treatment with sorafenib. Baylor University Medical Center Proceedings 34:3, pages 380-381.
Read now
Read now
Fang-jie Hou, Li-xiao Guo, Kai-yan Zheng, Jun-na Song, Qian Wang & Yu-guang Zheng. (2019) Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. OncoTargets and Therapy 12, pages 6685-6697.
Read now
Read now
Articles from other publishers (61)
Pulikkutty Subramaniyan, Yamunadevi Kandeepan, Shen-Ming Chen, Yun-Hao Chang, Heng-Yuan Hsu & Ming-Chin Yu. (2023) Enhanced electrochemical detection of sorafenib, an anticancer drug via CoGd-LDH modified glassy carbon electrode. Process Safety and Environmental Protection 178, pages 547-558.
Crossref
Crossref
Xueyan Sun, Zhizhong Xie, Xiaoyong Lei, Sheng Huang, Guotao Tang & Zhe Wang. (2023)
Research and development of
N
,
N
′-diarylureas as anti-tumor agents
. RSC Medicinal Chemistry 14:7, pages 1209-1226.
Crossref
Crossref
Chae Eun Jin, Moon Sup Yoon, Min Jeong Jo, Seo Yeon Kim, Jae Min Lee, Su Jeong Kang, Chun-Woong Park, Jin-Seok Kim & Dae Hwan Shin. (2023) Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy. Pharmaceutics 15:4, pages 1206.
Crossref
Crossref
Elena Kalinichenko, Aliaksandr Faryna, Tatyana Bozhok, Anna Golyakovich & Alesya Panibrat. (2023) Novel Phthalic-Based Anticancer Tyrosine Kinase Inhibitors: Design, Synthesis and Biological Activity. Current Issues in Molecular Biology 45:3, pages 1820-1842.
Crossref
Crossref
Elena G. Varlamova, Venera V. Khabatova, Sergey V. Gudkov & Egor A. Turovsky. (2023) Ca2+-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector. International Journal of Molecular Sciences 24:3, pages 2411.
Crossref
Crossref
Shanshan Liu, Yunwei Han, Zhihong Zhang & Fei Wu. (2023) Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study. Clinical Medicine Insights: Oncology 17, pages 117955492211466.
Crossref
Crossref
Amr Elagamy, Laila K. Elghoneimy & Reem K. Arafa. 2023. Recent Developments in the Synthesis and Applications of Pyridines. Recent Developments in the Synthesis and Applications of Pyridines
375
410
.
Sarada Prasad Dakua & Anchal Nayak. (2022) A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egyptian Liver Journal 12:1.
Crossref
Crossref
Tomoka Takao, Hirotaka Masuda, Takashi Kajitani, Fumie Miki, Kaoru Miyazaki, Yushi Yoshimasa, Satomi Katakura, Shoko Tomisato, Sayaka Uchida, Hiroshi Uchida, Mamoru Tanaka & Tetsuo Maruyama. (2022) Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway. Stem Cell Research & Therapy 13:1.
Crossref
Crossref
Wenjing Xu, Chunping Ye, Xin Qing, Shengli Liu, Xinyi Lv, Wenjun Wang, Xiaochen Dong & Yewei Zhang. (2022) Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Materials Today Bio 16, pages 100358.
Crossref
Crossref
A. A. Semenkin, V. S. Sapronenko, E. N. Loginova & E. V. Nadey. (2022) Targeted therapy in oncology. Experimental and Clinical Gastroenterology:9, pages 222-228.
Crossref
Crossref
Jingjing Ma, Fang Sui, Yan Liu, Mengmeng Yuan, Hui Dang, Rui Liu, Bingyin Shi & Peng Hou. (2022) Sorafenib decreases glycemia by impairing hepatic glucose metabolism. Endocrine 78:3, pages 446-457.
Crossref
Crossref
Yingqi Huang, Wei Liang, Kun Li, Xialin Liao, Jiawen Chen, Xiusheng Qiu, Kunpeng Liu, Dongbo Qiu & Yunfei Qin. (2022) Sorafenib suppresses the activation of type I interferon pathway induced by RLR-MAVS and cGAS-STING signaling. Biochemical and Biophysical Research Communications 623, pages 181-188.
Crossref
Crossref
Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li & Feng Chen. (2022) Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology 12.
Crossref
Crossref
Wenhui Wang, Fenqiang Li, Peiying Gan, Baohua Li & Shuangxi Li. (2022) Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer. Frontiers in Surgery 9.
Crossref
Crossref
Roberto Iezzi, Alessandro Posa, Marco Santoro, Alessandro Tanzilli, Lucia Cerrito, Francesca Romana Ponziani, Maurizio Pompili, Antonio Grieco, Gian Ludovico Rapaccini, Antonio Gasbarrini & Riccardo Manfredi. (2022) Balloon-Occluded Radiofrequency Ablation as Bridge to TACE in the
Treatment of Advanced HCC with Arterioportal Shunt. Current Radiopharmaceuticals 15:3, pages 194-198.
Crossref
Crossref
Hongyu Kong, Rong Zhang, Qinghe Jing, Yu Liang, Qiao Zhuo, Bo Li, Shujie Zhang, Weiliang Zhu & Chen Zhao. (2022) Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT/ERK1/2 pathway. Microvascular Research 143, pages 104401.
Crossref
Crossref
Hui Jiang, Cong Wang, An Zhang, Yufeng Li, Jianping Li, Zhan Li, Xin Yang & Yinglong Hou. (2022) ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomedicine & Pharmacotherapy 153, pages 113280.
Crossref
Crossref
Wendong Feng, Wendong Cao, Cunwei Cui & Xingtao Pi. (2022) Efficacy of Lipid Nanoparticle-Loaded Sorafenib Combined with Hepatic Artery Chemoembolization in the Treatment of Primary Hepatocellular Carcinoma Complicated with Microvascular Invasion. Disease Markers 2022, pages 1-9.
Crossref
Crossref
Aleksandra Majewska, Klaudia Brodaczewska, Aleksandra Filipiak-Duliban, Arkadiusz Kajdasz & Claudine Kieda. (2022) miRNA Pattern in Hypoxic Microenvironment of Kidney Cancer—Role of PTEN. Biomolecules 12:5, pages 686.
Crossref
Crossref
Andrea Luengas‐Martinez, Ralf Paus & Helen S. Young. (2022) A novel personalized treatment approach for psoriasis: anti‐vascular endothelial growth factor‐A (VEGF‐A) therapy. British Journal of Dermatology 186:5, pages 782-791.
Crossref
Crossref
Shu Wang, Bulin Du, Xuena Li & Yaming Li. (2022) A Renal Cyst Invaded by Infiltrating Renal Cell Carcinoma With Multiple Hypermetabolic Bone Metastases as the Initial Presentation. Clinical Nuclear Medicine 47:4, pages 369-371.
Crossref
Crossref
Lingyu Li, Lin Cheng, Ri Sa, Xian Qiu & Libo Chen. (2022) Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers. Critical Reviews in Oncology/Hematology 172, pages 103624.
Crossref
Crossref
Alexander Gudkov, Valery Shirokorad, Kirill Kashintsev, Dmitriy Sokov, Daniil Nikitin, Andrey Anisenko, Nicolas Borisov, Marina Sekacheva, Nurshat Gaifullin, Andrew Garazha, Maria Suntsova, Elena Koroleva, Anton Buzdin & Maksim Sorokin. (2022) Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Summer Sofer, Kevin Lamkiewicz, Shir Armoza Eilat, Shirly Partouche, Manja Marz, Neta Moskovits, Salomon M. Stemmer, Amir Shlomai & Ella H. Sklan. (2022) A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells. The FASEB Journal 36:3.
Crossref
Crossref
Lei Wang, Nanxi Wang, Wenping Zhang, Xurui Cheng, Zhibin Yan, Gang Shao, Xi Wang, Rui Wang & Caiyun Fu. (2022) Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Tianyu Qin & Gang Chen. (2022) Recent advances in targeted therapy for ovarian cancer. Oncology and Translational Medicine 8:1, pages 28-35.
Crossref
Crossref
Yingying Hu, Nan Guo, Ting Yang, Jianghong Yan, Wenjun Wang & Xiang Li. (2022) The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer. Oxidative Medicine and Cellular Longevity 2022, pages 1-12.
Crossref
Crossref
Vanita Marvaniya, Hirak V. Joshi, Ujashkumar A. Shah & Jayvadan K. Patel. (2022) Synthesis, Anticancer Evaluation and Molecular Docking Studies of
Isonicotinamide and Diaryl Urea Hybrid Motifs. Asian Journal of Organic & Medicinal Chemistry 7:2, pages 179-186.
Crossref
Crossref
Shohei YOKOTA, Tomohiro YONEZAWA, Yasuyuki MOMOI & Shingo MAEDA. (2022) Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. Journal of Veterinary Medical Science 84:5, pages 666-674.
Crossref
Crossref
JingJing Wu, XiaoJuan Tang, Yao Shi, ChangJu Ma, Hongyu Zhang, Junhong Zhang, Yue Lu, Jianan Wei, Li Li & Ling Han. (2022) Crosstalk of LncRNA HOTAIR and SP1-mediated repression of PDK1 contributes to β-Elemene-inhibited proliferation of hepatocellular carcinoma cells. Journal of Ethnopharmacology 283, pages 114456.
Crossref
Crossref
Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Ioana Anca Badarau, Andreea-Elena Scheau, Mircea Tampa, Simona Roxana Georgescu, Andreea Cristiana Didilescu, Cristian Scheau & Constantin Caruntu. (2021) Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Analytical Cellular Pathology 2021, pages 1-13.
Crossref
Crossref
Jingjing Wei, Yifeng Xia, Fenghua Meng, Dawei Ni, Xinyun Qiu & Zhiyuan Zhong. (2021) Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma. Biomacromolecules 22:11, pages 4814-4822.
Crossref
Crossref
Marta Ortega‐Muelas, Olga Roche, Diego M. Fernández‐Aroca, José A. Encinar, David Albandea‐Rodríguez, Elena Arconada‐Luque, Raquel Pascual‐Serra, Ismael Muñoz, Isabel Sánchez‐Pérez, Borja Belandia, María J. Ruiz‐Hidalgo & Ricardo Sánchez‐Prieto. (2021) ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. Journal of Cellular and Molecular Medicine 25:22, pages 10591-10603.
Crossref
Crossref
Zhichao Tian, Xiaohui Niu & Weitao Yao. (2021) Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. Frontiers in Oncology 11.
Crossref
Crossref
Marta Hałasa, Jarogniew J. Łuszczki, Magdalena Dmoszyńska-Graniczka, Marzena Baran, Estera Okoń, Andrzej Stepulak & Anna Wawruszak. (2021) Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin—An Isobolographic Analysis in Breast Cancer In Vitro Models. International Journal of Molecular Sciences 22:16, pages 8573.
Crossref
Crossref
Yu He, Yang Luo, Lan Huang, Dan Zhang, Xixi Wang, Jiayi Ji & Shufang Liang. (2021) New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacological Research 170, pages 105732.
Crossref
Crossref
Bin Wang, Lin Sun, Mingyun Wen, Youchun Tan, Waleed H. Almalki, Hanadi Katouah, Imran Kazmi, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, Fahad A. Al-Abbasi, Majed Alrobaian, Khalid S. Alharbi, Sattam K. Alenezi, Adel F. Alghaith, Sarwar Beg & Mahfoozur Rahman. (2021) Nano lipidic carriers for codelivery of sorafenib and ganoderic acid for enhanced synergistic antitumor efficacy against hepatocellular carcinoma. Saudi Pharmaceutical Journal 29:8, pages 843-856.
Crossref
Crossref
Xiaofeng Dai, Danjun Wang & Jianying Zhang. (2021) Programmed cell death, redox imbalance, and cancer therapeutics. Apoptosis 26:7-8, pages 385-414.
Crossref
Crossref
David E. Heppner & Michael J. Eck. (2021)
A structural perspective on targeting the
RTK
/Ras/
MAP
kinase pathway in cancer
. Protein Science 30:8, pages 1535-1553.
Crossref
Crossref
Lingyue Gao, Zhuo-Xun Wu, Yehuda G. Assaraf, Zhe-Sheng Chen & Lihui Wang. (2021) Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resistance Updates 57, pages 100770.
Crossref
Crossref
Albert Caballeria-Casals, Marc Micó-Carnero, Carlos Rojano-Alfonso, Cristina Maroto-Serrat, Araní Casillas-Ramírez, Ana I. Álvarez-Mercado, Jordi Gracia-Sancho & Carmen Peralta. (2021) Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde?. Cells 10:6, pages 1421.
Crossref
Crossref
Jieun Kim, Jin-Hee Park, Seon Kyeong Park & Hyang-Sook Hoe. (2021) Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice. Frontiers in Immunology 12.
Crossref
Crossref
Ki-Young Huh, Se-jung Hwang, Sang-Yeob Park, Hye-Jung Lim, Mir-yung Jin, Jae-seong Oh, Kyung-Sang Yu & Jae-Yong Chung. (2021) Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib. Pharmaceutics 13:5, pages 629.
Crossref
Crossref
Manuela Santonocito, Cristina Zappulla, Santa Viola, Luca Rosario La Rosa, Elena Solfato, Ilenia Abbate, Valeria Tarallo, Ivana Apicella, Chiara Bianca Maria Platania, Grazia Maugeri, Velia D’Agata, Claudio Bucolo, Sandro De Falco, Maria Grazia Mazzone & Francesco Giuliano. (2021) Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. International Journal of Molecular Sciences 22:9, pages 4404.
Crossref
Crossref
Valentina Tateo, Lisa Manuzzi, Claudia Parisi, Andrea De Giglio, Davide Campana, Maria Abbondanza Pantaleo & Giuseppe Lamberti. (2021) An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals 14:4, pages 316.
Crossref
Crossref
Huili Lai, Liping Zhong, Yong Huang, Yongxiang Zhao & Zhiyong Qian. (2021) Progress in Application of Nanotechnology in Sorafenib. Journal of Biomedical Nanotechnology 17:4, pages 529-557.
Crossref
Crossref
Guihong Liu, Tao Chen, Zhenyu Ding, Yang Wang, Yuquan Wei & Xiawei Wei. (2021) Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment. Cell Proliferation 54:4.
Crossref
Crossref
Hexu Han, Ting Lin, Ziyi Fang & Guoxiong Zhou. (2021) RBM23 Drives Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway. BioMed Research International 2021, pages 1-9.
Crossref
Crossref
Nico Gagelmann, Christine Wolschke, Evgeny Klyuchnikov, Maximilian Christopeit, Francis Ayuk & Nicolaus Kröger. (2021) TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Frontiers in Immunology 12.
Crossref
Crossref
Frederik A. Verburg, Holger Amthauer, Ina Binse, Ingo Brink, Andreas Buck, Andreas Darr, Christine Dierks, Christine Koch, Ute König, Michael C. Kreissl, Markus Luster, Christoph Reuter, Klemens Scheidhauer, Holger Sven Willenberg, Andreas Zielke & Matthias Schott. (2021) Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Hormone and Metabolic Research 53:03, pages 149-160.
Crossref
Crossref
Guang-Lin Lei, Hong-Xia Fan, Cheng Wang, Yan Niu, Tie-Ling Li, Ling-Xiang Yu, Zhi-Xian Hong, Jin Yan, Xi-Liang Wang, Shao-Geng Zhang, Ming-Ji Ren & Peng-Hui Yang. (2021) Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma. World Journal of Gastroenterology 27:1, pages 55-68.
Crossref
Crossref
Alessia Catalano, Domenico Iacopetta, Maria Stefania Sinicropi & Carlo Franchini. (2021) Diarylureas as Antitumor Agents. Applied Sciences 11:1, pages 374.
Crossref
Crossref
Haiyin Wang, Chunlin Jin, Liang Fang, Hui Sun, Wendi Cheng & Shanlian HU. (2020) Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
Ingrid Lilienthal & Nikolas Herold. (2020) Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. International Journal of Molecular Sciences 21:18, pages 6885.
Crossref
Crossref
Zhichao Tian, Xiaohui Niu & Weitao Yao. (2020) Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?. Frontiers in Oncology 10.
Crossref
Crossref
Yichao Wan, Chunxing Yan, Han Gao & Tingting Liu. (2020) Small-molecule PROTACs: novel agents for cancer therapy. Future Medicinal Chemistry 12:10, pages 915-938.
Crossref
Crossref
Wenxiao Jiang, Jun Xia, Shangdan Xie, Ruanmin Zou, Shuya Pan, Zhi-wei Wang, Yehuda G. Assaraf & Xueqiong Zhu. (2020) Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resistance Updates 50, pages 100683.
Crossref
Crossref
Agnieszka Karbownik, Anna Stachowiak, Hanna Urjasz, Katarzyna Sobańska, Agnieszka Szczecińska, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Anna Wolc, Edmund Grześkowiak & Edyta Szałek. (2020) The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats. Pharmacological Reports 72:1, pages 254-259.
Crossref
Crossref
Hiroto Inaba, John C. Panetta, Stanley B. Pounds, Lei Wang, Lie Li, Fariba Navid, Sara M. Federico, Eric D. Eisenmann, Aksana Vasilyeva, Yong-Dong Wang, Sheila Shurtleff, Ching-Hon Pui, Tanja A. Gruber, Raul C. Ribeiro, Jeffrey E. Rubnitz & Sharyn D. Baker. (2019) Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research 25:24, pages 7320-7330.
Crossref
Crossref
Francesco Palomba, Damiano Genovese, Enrico Rampazzo, Nelsi Zaccheroni, Luca Prodi & Lucia Morbidelli. (2019) PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells. ACS Omega 4:9, pages 13962-13971.
Crossref
Crossref